Popular on Amzeal
- Elixia Announces New Hire Sam Searcy as Chief Commercial Officer
- New "Perfect Home Finder" Real Estate Program Huge Hit With Central OH Home Buyers!
- Accendo's Talent Intelligence Platform Secures Pre-Series A Funding from The Hive SEA and OSK Ventures
- Guaranteed Full Price Home Sale in Phoenix West Valley! Sell Your House For Top Dollar Without The Hassle of Listing or Showings!
- Phoreus Biotech launches BAPtofect®-25 peptide transfection reagent
- iGUIDE Announces Latest Partnership with AMS Workplace Technology
- Luxury Presence Announces New Chief Customer Officer
- Buying Buddy Launches Duda Real Estate Plugin
- The Official Drink Of Juneteenth Atlanta 2023
- Counsel from Irell & Manella LLP, Sandoz and Bristol Myers Squib to Chair ACI's Paragraph IV Disputes this April in NYC
Similar on Amzeal
- Sherry Orel Joins STS Capital Partners
- Matt Fogelgren to Join Cleartelligence Executive Team as Chief Revenue Officer
- Orbex Introduces Double Profits for New Traders
- Quotehunt.co.uk: Revolutionising the UK B2B Market with Comprehensive Comparison Services for Small Businesses
- Jennifer S. Wilkov Finalizes Lineup for the 2023 April Speak Up Women Conference
- Doug Brownridge Joins STS Capital Partners
- Cash Depot Appoints Tony Gaines as Chief Revenue Officer and Brand Ambassador
- Eddie Turner is Recognized as the #9 Motivational Speaker in the World By Global Gurus!
- Wohler releases out-of-band configuration tools for Riedel 2110 SFP's
- Levinger Regens Announces New Initiative to Improve Hydrogen Carbon Intensity
CATALENT DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Catalent To Contact Him Directly To Discuss Their Options
Amzeal News/10518356
NEW YORK, March 18, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Catalent, Inc. ("Catalent" or the "Company") (NYSE: CTLT) and reminds investors of the April 25, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
If you suffered losses exceeding $100,000 investing in Catalent stock or options between August 30, 2021 and October 31, 2022, both dates inclusive (the "Class Period") and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/CTLT.
There is no cost or obligation to you.
Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
Catalent is a multinational corporation that manufactures and packages drugs into delivery devices fit for human consumption (i.e., pre-filled syringes, vials, pills, etc.) pursuant to long-term supply contracts with pharmaceutical companies. Catalent directly sells these products to pharmaceutical companies which later sell them through the supply chain to healthcare providers (i.e., hospitals, clinics, etc.), which administer them to patients, who are the end consumers. Catalent's vaccine manufacturing business initially benefitted from the COVID-19 pandemic, causing its stock price to soar to record highs.
More on Amzeal News
The Complaint alleges that by mid-2021, when COVID-related work dropped off, Defendants engaged in accounting and channel stuffing schemes to pad the Company's revenues. These schemes gave Catalent the appearance of continued growth, causing its stock price to reach record highs. Meanwhile, to support these schemes and keep pace with its lofty growth targets, Catalent was cutting corners on safety and control procedures at key production facilities. By late 2022, Catalent reported significant sales declines and excess inventory throughout its supply chain. As a result, Catalent stock dropped to pre-COVID levels causing substantial losses to its investors as they learned that Catalent's early-COVID revenues were never sustainable, and its Class Period revenues were the product of securities fraud.
The Complaint further alleges that statements made by Defendants throughout the Class Period were materially false and misleading when made because they misrepresented or failed to disclose the following adverse facts, which were known to Defendants or recklessly disregarded by them: (a) Catalent materially overstated its revenue and earnings by prematurely recognizing revenue in violation of U.S. Generally Accepted Accounting Principles ("GAAP"); (b) Catalent had material weaknesses in its internal control over financial reporting related to revenue recognition; (c) Catalent falsely represented demand for its products while it knowingly sold more product to its direct customers than could be sold to healthcare providers and end consumers; (d) Catalent disregarded regulatory rules at key production facilities in order to rapidly produce excess inventory that was used to pad the Company's financial results through premature revenue recognition in violation of GAAP and/or stuffing its direct customers with this excess inventory; and (e) as a result of the foregoing, Defendants lacked a reasonable basis for their positive statements about the Company's financial performance, outlook, and regulatory compliance during the Class Period.
More on Amzeal News
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Catalent's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
SOURCE Faruqi & Faruqi, LLP
If you suffered losses exceeding $100,000 investing in Catalent stock or options between August 30, 2021 and October 31, 2022, both dates inclusive (the "Class Period") and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/CTLT.
There is no cost or obligation to you.
Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
Catalent is a multinational corporation that manufactures and packages drugs into delivery devices fit for human consumption (i.e., pre-filled syringes, vials, pills, etc.) pursuant to long-term supply contracts with pharmaceutical companies. Catalent directly sells these products to pharmaceutical companies which later sell them through the supply chain to healthcare providers (i.e., hospitals, clinics, etc.), which administer them to patients, who are the end consumers. Catalent's vaccine manufacturing business initially benefitted from the COVID-19 pandemic, causing its stock price to soar to record highs.
More on Amzeal News
- Arbutus Medical Launches TrakPak® with QuikBow™ to Improve Skeletal Traction, Announces Successful Cases
- Jivaso Launches Peer-to-Peer (P2P) Business Platform for Small Businesses in March 2023
- Waterleaf International, LLC Announces Hiring of Chief Sales Officer
- EVERWILD Returns To Legend Valley With Lineup Featuring Pepper, Bone Thugs-N-Harmony, and host band Tropidelic
- SystemSeed Shortlisted for 2023 Global Business Tech Awards in Tech For Good Category for Project with War Child and George Washington University
The Complaint alleges that by mid-2021, when COVID-related work dropped off, Defendants engaged in accounting and channel stuffing schemes to pad the Company's revenues. These schemes gave Catalent the appearance of continued growth, causing its stock price to reach record highs. Meanwhile, to support these schemes and keep pace with its lofty growth targets, Catalent was cutting corners on safety and control procedures at key production facilities. By late 2022, Catalent reported significant sales declines and excess inventory throughout its supply chain. As a result, Catalent stock dropped to pre-COVID levels causing substantial losses to its investors as they learned that Catalent's early-COVID revenues were never sustainable, and its Class Period revenues were the product of securities fraud.
The Complaint further alleges that statements made by Defendants throughout the Class Period were materially false and misleading when made because they misrepresented or failed to disclose the following adverse facts, which were known to Defendants or recklessly disregarded by them: (a) Catalent materially overstated its revenue and earnings by prematurely recognizing revenue in violation of U.S. Generally Accepted Accounting Principles ("GAAP"); (b) Catalent had material weaknesses in its internal control over financial reporting related to revenue recognition; (c) Catalent falsely represented demand for its products while it knowingly sold more product to its direct customers than could be sold to healthcare providers and end consumers; (d) Catalent disregarded regulatory rules at key production facilities in order to rapidly produce excess inventory that was used to pad the Company's financial results through premature revenue recognition in violation of GAAP and/or stuffing its direct customers with this excess inventory; and (e) as a result of the foregoing, Defendants lacked a reasonable basis for their positive statements about the Company's financial performance, outlook, and regulatory compliance during the Class Period.
More on Amzeal News
- Deputy Minister of Digital Transformation Ukraine and Ukraine Drone Reconnaissance Speaking at ACI
- edjuster Streamlines Insurance Claims Process with Enhanced Digital Platform Release
- World's First AI-Generated Satirical News Website Launches, Outperforms Humans in Humor and Intelligence
- Genie Script: 20 Word Script by Wesley Virgin
- The Impact Of Cybercrime On Families in 2023
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Catalent's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
SOURCE Faruqi & Faruqi, LLP
Filed Under: Business
0 Comments
Latest on Amzeal News
- 2023 National Farmworker Awareness Week
- Orbex Introduces Double Profits for New Traders
- Quotehunt.co.uk: Revolutionising the UK B2B Market with Comprehensive Comparison Services for Small Businesses
- Dr. Kelli Ward and Martha Boneta Fain join the advisory board of Legacy PAC , a partner of Veterans for Trump
- 2023 Employee Handbook Templates Now Available
- Andromeda Galactic Solutions Continues Fundraising for Extra Life
- Martine Dowden Co-Authors "Tiny CSS Projects"
- Mercy Street to Host the Largest Opening Day Event in the Organization's 20 Year History
- The Nashville International Chopin Piano Competition Announces the Alexei Sultanov Memorial Discovery Prize
- FlexCare Infusion Centers Chooses MedEdge Solutions', IDRx, for License Verification Platform
- Vault Innovation Group (VAULT) is celebrating 10 years of growth and innovation
- Kobie Voted a Top Workplace USA
- Aquia Inc. Joins the AWS Partner Network and the AWS Public Sector Partner Program
- Perfect Body Laser and Aesthetics ® Offers Tetra CoolPeel Co2 Laser Skin Resurfacing
- Databloom's Blossom Achieves Faster and More Efficient Big Data Analytics
- Orchard Audio's New PecanPi®+ DAC and Streamer Feature AKM's Latest Flagship Chips
- Country Artist Ashley Wineland to Release Poignant Ballad 'I'm Going Home'; Announces Her 2023 National Tour
- Jennifer S. Wilkov Finalizes Lineup for the 2023 April Speak Up Women Conference
- SkillGigs, Inc. Announces Hire of Rasha Sammour as Human Resources Director
- Doug Brownridge Joins STS Capital Partners